Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Int J Mol Sci ; 19(11)2018 Nov 09.
Artigo em Inglês | MEDLINE | ID: mdl-30423942

RESUMO

The development of new and better implant materials adapted to osteoporotic bone is still urgently required. Therefore, osteoporotic muscarinic acetylcholine receptor M3 (M3 mAChR) knockout (KO) and corresponding wild type (WT) mice underwent osteotomy in the distal femoral metaphysis. Fracture gaps were filled with a pasty α-tricalcium phosphate (α-TCP)-based hydroxyapatite (HA)-forming bone cement containing mesoporous bioactive CaP-SiO2 glass particles (cement/MBG composite) with or without Brain-Derived Neurotrophic Factor (BDNF) and healing analyzed after 35 days. Histologically, bone formation was significantly increased in WT mice that received the BDNF-functionalized cement/MBG composite compared to control WT mice without BDNF. Cement/MBG composite without BDNF increased bone formation in M3 mAChR KO mice compared to equally treated WT mice. Mass spectrometric imaging showed that the BDNF-functionalized cement/MBG composite implanted in M3 mAChR KO mice was infiltrated by newly formed tissue. Leukocyte numbers were significantly lower in M3 mAChR KO mice treated with BDNF-functionalized cement/MBG composite compared to controls without BDNF. C-reactive protein (CRP) concentrations were significantly lower in M3 mAChR KO mice that received the cement/MBG composite without BDNF when compared to WT mice treated the same. Whereas alkaline phosphatase (ALP) concentrations in callus were significantly increased in M3 mAChR KO mice, ALP activity was significantly higher in WT mice. Due to a stronger effect of BDNF in non osteoporotic mice, higher BDNF concentrations might be needed for osteoporotic fracture healing. Nevertheless, the BDNF-functionalized cement/MBG composite promoted fracture healing in non osteoporotic bone.


Assuntos
Cimentos Ósseos/uso terapêutico , Fator Neurotrófico Derivado do Encéfalo/uso terapêutico , Fêmur/patologia , Consolidação da Fratura/efeitos dos fármacos , Vidro/química , Fraturas por Osteoporose/tratamento farmacológico , Fosfatase Alcalina/metabolismo , Animais , Cimentos Ósseos/farmacologia , Calo Ósseo/efeitos dos fármacos , Calo Ósseo/enzimologia , Calo Ósseo/patologia , Fator Neurotrófico Derivado do Encéfalo/farmacologia , Proteína C-Reativa/metabolismo , Modelos Animais de Doenças , Feminino , Fêmur/diagnóstico por imagem , Fêmur/efeitos dos fármacos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Fraturas por Osteoporose/sangue , Fraturas por Osteoporose/diagnóstico por imagem , Fraturas por Osteoporose/patologia , Porosidade , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Receptor Muscarínico M3/metabolismo , Espectrometria por Raios X , Microtomografia por Raio-X
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA